Skip to main content
T Cell Image

T Cells

T cells are responsible for cell-mediated immunity. Redirect T cells to target specific tumor cell populations with cell therapies such as CAR-T and TCR.

NK Cell Image

Natural Killer (NK) Cells

NK cells are lymphocytes critical to the innate immune system. Engineer the MHC-independent cytolytic activity of NK cells by introducing CARs and modulating their activating and inhibitory receptors.

image of T Cell-Based Therapies eBook

This new eBook provides an overview of several biological and manufacturing challenges facing the development and production of T cell therapies. It follows with examples of how Bio-Techne products and services can address these challenges at each stage of the process.

Treg Cell Image

Regulatory T Cells (Treg)

Treg cells control the immune system by regulating cells for an immune response. Deploy the immunosuppressive function of regulatory T cells to limit the severity of autoimmune diseases.

 

B Cell Image

B Cells

B cells are known for antibody-mediated immunity. Target overactive B cells in autoimmune diseases with engineered cells that express CAR constructs.

 

Dendritic Immune Cell

Dendritic Cells

Dendritic cells are antigen-presenting cells. Regulate host anti-tumor immunity and develop tolerogenic DC and cancer vaccines by tuning DC function.

 

What Is Immune Cell Therapy?

Immune cell therapy is an extremely promising approach for the treatment of many diseases with an immune component including cancer, autoimmune disease, and chronic inflammation. In many immune cell therapies, specific cell populations are isolated, genetically modified, activated, and expanded to the large numbers required for patient treatment. T cells, NK cells, regulatory T cells (Treg cells), or dendritic cells can be redirected to attack tumors or amplify a local immune response. The immunosuppressive function of Treg cells allows therapies that specifically target an overactive immune system such as in autoimmune disease.

Gene engineering, either by non-viral transposon systems or virus-based methods, can introduce chimeric antigen receptors (CAR), T cell receptors (TCR), or other proteins to enhance the intended therapeutic activity. It is important to characterize cell phenotype and function throughout the manufacturing process to ensure high quality of the final cell product. Rigorous cell characterization is critical to ensure that your cell product is the correct cell type, shows the correct secretory profile, and is free of undesired cells or contaminants.

ScaleReady Logo

Bio-Techne believes in the power of partnerships. We have joined with Fresenius Kabi and Wilson Wolf to bring you ScaleReady™, lowering the barriers to entry into the immune cell therapy space for all sizes and stages of manufacturing programs. ScaleReady brings cell and gene therapies to life by offering a significant reduction of complexity and cost while consistently providing superior repeatability and cell quality.

The ScaleReady product portfolio supports scalable immune cell therapy solutions, delivering true platform, process, and product continuity for your immune cell programs. When paired with the Lovo® and Cue® functionally-closed-system automated cell processing systems, Bio-Techne reagents and the G-Rex® Bioreactor enable high throughput parallel processing of cell therapies within a small footprint.